Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.
"Be the change you wish to see in the world..." Gandhi
ANGEL’S STORY - as told by Angel's mother
On May 4, 2018 Angel Carden was like any ordinary 8 year old boy. He was just finishing up 3rd grade and enjoying the last days of Little League Baseball. After a day on the baseball field, Angel started to have seizures later on that night. We rushed him to an emergency room and a CT scan discovered that Angel had a large tumor growing in the back of his brain. Our world felt like it was ending, we were scared, and we desperately feared for our son’s dear life.
Angel was immediately transferred by ambulance to Phoenix Children’s Hospital, only one of a few places in the country that could properly care for our son. By the time we were admitted the tumor was causing increased pressure to his brain. This caused Angel to continuously vomit, barely speak, unable to move and started to lose his vision. Angel’s neurosurgeon Dr. Ruth Bristol was the one to diagnose our son with Stage 4 Medulloblastoma. She let us know that he had to immediately have surgery for 2 shunts, to relieve the pressure on his brain before any permanent damage was done. We spent 14 days in the Pediatric Intense Care Unit and Angel’s final surgery lasted over 7 hours to remove his brain tumor.
We prayed so much during that time, and had started to meet so many new people that cared for our son as much as we did. After the surgery Angel could barely move or talk, which is common with posterior fossa syndrome. When we left the hospital at the end of May, Angel was in a wheelchair and his Dad had to lift him into our car to take him home. Every day I watch my son defy the odds against him. He went to physical, speech, and occupational therapy; exceeded every goal they set for him in the span of 4 months. Since then Angel has went on to complete Proton Radiation Therapy as Scottsdale Mayo Clinic under Dr. Sameer Keole for about 8 weeks. He now walks, talks, and went from writing with his left hand to right hand. Angel is even going to school when he feels up to it. Angel just wanted to share his story to never give up, and he wants to give back for every child that may be going through the same circumstance that Angel has been through.
PLEASE SUPPORT SSBTR to help Angel and the far too many like him!
“It is every man's obligation to put back into the world at least the equivalent of what he takes out of it.”
— Albert Einstein
A new blood test that can detect brain cancer has been developed in the United Kingdom. It’s cutting edge technology uses artificial intelligence and has a high accuracy rate. This new blood test sounds very promising. Now what the researchers did was to use an infrared light technique to produce what’s called a biochemical ‘fingerprint’.
Researchers for the University of Strathclyde have developed the test, which uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer.
Researchers at Tufts University have just developed a way to create an environment that closely mimics that of the brain and were able to grow pediatric and adult tumors within it. The microenvironment allows for non-invasive imaging of the tumors and for easy manipulation of the cells growing within.
Tiny bubbles in the brain might offer some respite for some. An experiment using those bubbles to help treatment drugs get to places normally out of reach. The technique could give patients with glioblastomas far longer lives. It could also offer a way to treat other devastating brain diseases such as Alzheimer’s and Parkinson’s.
Ribociclib, a drug that was recently FDA-approved for breast cancer, is part of a new class of drugs that target cell division thereby suppressing cancer progression.
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
